◀ Back to EPO

EPO — IL9

Text-mined interactions from Literome

Fandrey et al., Ann N Y Acad Sci 1991 (Carcinoma, Hepatocellular...) : A dose dependent decrease of up to 60 % in Epo production was induced by interleukin-1 beta, interleukin-1 alpha, and tumor necrosis factor-alpha ( in that order of potency )
Ghinassi et al., Exp Hematol 2007 : These results suggest that interleukin-3 and erythropoietin cooperate to establish the lineage-specific transcription factor milieu of erythroid cells : interleukin-3 regulates mainly gene transcription and erythropoietin consistently increases mRNA and protein stability
Lifshitz et al., Haematologica 2010 : The macrophages derived in-vitro from bone marrow cells expressed erythropoietin receptor transcripts, and in-vitro stimulation with erythropoietin activated multiple signaling pathways, including signal transducer and activator of transcription ( STAT ) 1 and 5, mitogen activated protein kinase, phosphatidylinositol 3-kinase and nuclear factor kappa B. In-vitro erythropoietin treatment of these cells up-regulated their surface expression of CD11b, F4/80 and CD80, enhanced their phagocytic activity and nitric oxide secretion, and also led to augmented interleukin 12 secretion and decreased interleukin 10 secretion in response to lipopolysaccharide
Schaafsma et al., Ann Hematol 1993 : In the presence of erythropoietin , IL-9 was found to stimulate the proliferation of relatively early erythroid progenitor cells ( BFU-E ) from normal human bone marrow cells depleted of mononuclear phagocytes and T lymphocytes